Home2026-06-09T11:19:10-04:00

Our Vision

Transform the pen needle category from commoditized delivery devices into clinically valuable
tools that improve diabetes outcomes.

Our Belief

For decades, innovation in pen needles focused primarily on physical engineering — sharper tips, thinner gauges, optimized hub geometry, and reduced needle length. While these advancements improved usability incrementally, the category has reached a point of diminishing returns.

We believe the next era of differentiation will be driven not only by hardware design, but also by clinical and behavioral innovation that helps patients use injection therapy more effectively and consistently to improve outcomes. Innovation that counts!

“Ensuring healthy insulin injection site rotation has not only been shown to improve the efficiency of insulin, but has also been shown to better patient glycemic outcomes and broader healthcare system value.

Our Focus

“How and where you inject is as important as what you inject.”

While insulin therapies and delivery hardware have continued to evolve, injection site management remains a significantly under-addressed component of diabetes care.

Poor injection site rotation can lead to lipohypertrophy, a common complication associated with inconsistent insulin absorption, increased glycemic variability, elevated insulin requirements, and suboptimal glycemic control. 1,2

Although proper site rotation is a globally recognized clinical recommendation, adherence remains difficult in real-world practice due to the behavioral and cognitive burden associated with insulin therapy.2
Multiple published studies have demonstrated that intensive injection site rotation education programs, combined with frequent healthcare professional follow-ups, can improve glycemic outcomes, including HbA1c. However, these improvements tend to diminish once regular follow-up support is discontinued, highlighting the ongoing behavioral and healthcare resource utilization challenges associated with sustaining injection site rotation practices.3,4,5,6

We believe improving injection behaviors represents the simplest, yet under-addressed opportunity to enhance clinical and financial outcomes in insulin therapy.

Our Clinically Proven Solution

SiteSmart™ was developed to address one of the most persistent and under-addressed behavioral challenges in insulin therapy: sustained adherence to healthy injection site rotation practices.

Rather than relying on complex digital tools, repeated educational interventions, or intensive follow-up programs, SiteSmart™ integrates behavioral guidance directly into the pen needle through a patented and intuitive color-based system designed to help insulin users seamlessly implement a structured injection site rotation routine in their day-to-day lives. SiteSmart™ transforms the utility of a pen needle from solely a delivery device to a clinically valuable tool to teach and implement a healthy injection site rotation routine for better clinical outcomes in insulin therapy.

Each SiteSmart™ package contains pen needles marked with four distinctive colors that patients associate with different injection areas as part of a personalized site rotation plan. This simple behavioral framework helps reinforce healthy injection habits without adding to the cognitive burden associated with diabetes management.

The SiteSmart™ technology has been clinically proven to improve injection site rotation behaviors in a pharmacy-based randomized controlled trial. 7 In the study, the sole dispensing of SiteSmart™ by retail pharmacists resulted in a statistically significant improvement in injection site rotation compared to conventional pen needles.

The study further demonstrated how a simple, low-tech, and scalable intervention integrated into standard pharmacy workflow may represent a practical opportunity to improve injection behaviors and support better diabetes management outcomes.

SITE SMART

How it works

You must be asking… how does it work?

SiteSmart™ leverages the basic principle of association to create and favor effortless implementation of healthy insulin injection site rotations. First, create your injection site rotation plan according to your preference and your healthcare professional recommendations by simply associating a color to an injection site, using the association tool provided in the box, or by using the web app. Then, each time you pick a new pen needle, simply inject in the area corresponding to the color of the pen needle on your plan.

4 COLORS OF PEN NEEDLES

100 pen needles per box distinctively marked with 4 colors (4×25)

INJECTION SITES ASSOCIATION TOOLS

Association tools included in the box or available online

That’s it! No tracking, no logging, no need to remember where you gave your last injection. It’s that easy!

SITE SMART

Leadership

Our team has years of professional (and personal) experience in diabetes and blood sugar management, delivery systems, and commercialization.

amir farzam

President and CEO

Amir has worked for more than 20 years as an entrepreneur and CEO in diabetes medical device commercialization as well as not-for-profit diabetes education. His expertise is developing company strategy while leading all operational tactics and building business models anchored in innovation. Prior to Montmed, Amir co-founded and led Farir Teb, an Iran-based medical device company, which became the market leader of diabetes devices in Iran over a period of 5 years. He also co-founded and sat on the board of directors of Gabric Diabetes Education Association, which became the best practice of diabetes education in MENA (Middle-East and North Africa), member of IDF (International Diabetes Federation) and recognized by WHO. (World Health Organization) Amir is driven by the complexity of diabetes management, a combination of science and consumer behavior.

MARTIN LAFONTAINE

Head of Commercial and Business Development

Martin has more than 25 years of experience within the pharmaceutical, medical device and digital health industry. He possesses strong expertise in commercial go-to-market product launch excellence, marketing, corporate development and business development, in Canada, US and internationally. Martin recently acted as a consultant to numerous development-stage pharmaceutical and medical device companies, in the field of diabetes. Prior to this, Martin held the role of Chief Commercial Officer for Locemia Solutions, a Montreal based company developing nasal glucagon for the rescue treatment of hypoglycemia, acquired by Eli Lilly in 2015. His passion for diabetes has solid roots, beginning at age 13 when he was diagnosed with type 1 diabetes.
He authored a chapter in the book, “Successful Men With Diabetes.”

Board of Directors

Chairman of the Board

As Co-Founder, President and CEO of Locemia Solutions, Dr. Piché led the company from start up through to completion of phase III clinical studies, ultimately resulting in the sale of its glucagon nasal powder technology to Eli Lilly in October 2015. He has over 25 years of experience in developing and commercializing pharmaceuticals, vaccines, and diagnostics, including more than 15 years where he focused on diabetes therapeutics and hypoglycemia-related technologies. He has worked at large companies such as Merck, as well as start-up biopharmaceutical companies where he had roles in research, regulatory affairs, marketing, and operations.

Board Member

Amir has worked for 13 years as an entrepreneur and CEO in diabetes medical device commercialization as well as not-for-profit diabetes education. His expertise is developing company strategy while leading all operational tactics and building business models anchored in innovation. Prior to Montmed, Amir co-founded and led Farir Teb, an Iran-based medical device company, which became the market leader of diabetes devices in Iran over a period of 5 years. He also co-founded and sat on the board of directors of Gabric Diabetes Education Association, which became the best practice of diabetes education in MENA (Middle-East and North Africa), member of IDF (International Diabetes Federation) and recognized by WHO. (World Health Organization) Amir is driven by the complexity of diabetes management, a combination of science and consumer behavior.

Board Member

Living with T1 diabetes since the age of 14 together with his attitude of creativity, Hormoz co-founded Gabric Diabetes Education Association in 2006. As a unique diabetes school and support model, combining technology, empathy and innovation, Gabric has tremendously revolutionized the lives of hundreds of thousands of people with diabetes all over Iran. Gabric is recognized by WHO as one of the leading role models. He also co-founded Farir-Teb implementing a unique business model in Iran offering a wide variety of healthcare products with focus on diabetes gaining significant market share in a short-run. Having valuable experience in strategy, marketing, leadership and non-profit, Hormoz is also an advisor and a leadership instructor for non-for-profit organizations.

Latest News

1305, 2025

Montmed take back distribution of its innovation SiteSmart from Roche.

Montmed announced that it has resumed direct distribution and commercialization of SiteSmart®, regaining full control of the product's strategic direction and market development activities. The transition strengthens Montmed's ability to pursue new partnerships, accelerate market expansion, and further enhance the [...]

Read More
1610, 2020

Randomized Controlled Trial Validates Clinical Benefits of SiteSmart

Results from a randomized controlled trial evaluating SiteSmart® were published in Diabetes Therapy, providing independent clinical validation of Montmed's patented injection site rotation solution. The study demonstrated that the sole dispensing of SiteSmart® by retail pharmacists resulted in a statistically [...]

Read More

Let’s Talk

Have a question for us? Let us know how can we help.

    EnglishFrançais

    CORPORATE HEADQUARTERS

    Montméd Inc.

    1275 Avenue des Canadiens-de-Montréal, Suite 500,

    Montreal, QC H3B 0G4

    Canada

    References 1. Frid AH, Hirsch LJ, Menchior AR, Morel DR, Strauss KW. Worldwide Injection Technique Questionnaire Study: Population Parameters and Injection Practices. Mayo Clin Proc. 2016 Sep;91(9):1212-23. doi: 10.1016/j.mayocp.2016.06.011. PMID: 27594185.Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Blanco M, et al. Diabetes Metab (2013), http://dx.doi.org/10.1016/j.diabet.2013.05.006. | 2. Optimizing insulin injection techniques and its effect on blood glucose control. Grassi G, Scuntero P, Trepiccioni R, et al. J Clin Transl Endocrinol. 2014;1:145-150. | 3. An Effective Intervention for Diabetic Lipohypertrophy: Results of a Randomized, Controlled, Prospective Multicenter Study in France. Campinos and al. Diabetes technology and Therapeutics, 2017 | 4. A Randomized Controlled Trial to Assess the Impact of Proper Insulin Injection Technique Training on Glycemic Control. Misnikova et al. Diabetes Ther (2017) 8:1309–1318 | 5. Gentile S, Guarino G, Della Corte T, Marino G, Satta E, Pasquarella M, Romano C, Alfrone C, Giordano L, Loiacono F, Capace M, Lamberti R, Strollo F; AMD-OSDI Study Group on Injection Technique; Nefrocenter Research and Nyx Start-Up Study Group. The Durability of an Intensive, Structured Education-Based Rehabilitation Protocol for Best Insulin Injection Practice: The ISTERP-2 Study. Diabetes Ther. 2021 Sep;12(9):2557-2569. doi: 10.1007/s13300-021-01108-9. Epub 2021 Aug 12. PMID: 34383261; PMCID: PMC8385007 | 6. Berard LD, Pockett SA, Roscoe RS, Siemens RL. A Coloured Pen Needle Education System Improves Insulin Site Rotation Habits: Results of a Randomized Study. Diabetes Ther. 2020 Dec;11(12):2979-2991. doi: 10.1007/s13300-020-00939-2. Epub 2020 Oct 16. PMID: 33064250; PMCID: PMC7644732.

    Share this with ordering colleague.

    Go to Top